BiotechTube
Neuron23

Neuron23

South San Francisco, United States· Est.
neuron23.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $313.5M

Overview

Neuron23 is a private, clinical-stage biotech founded in 2018 that is pioneering a precision medicine paradigm for Parkinson's disease and other neurological conditions. Its core strategy integrates AI/ML-driven target discovery with the development of potentially best-in-class therapies, led by its lead asset NEU-411, a brain-penetrant LRRK2 inhibitor now in a global Phase 2 trial for genetically defined Parkinson's. The company is backed by significant venture capital, including a recent $96.5 million Series D, and is led by a team with deep expertise in neuroscience and drug development. Neuron23 aims to subset patient populations based on genetic drivers, similar to oncology, to deliver more effective treatments.

NeurologyImmunology

Technology Platform

Integrated AI/ML and human genetics platform for target discovery and patient stratification in neurological and immunological diseases.

Funding History

3
Total raised:$313.5M
Series C$100M
Series B$113.5M
Series A$100M

Opportunities

The primary opportunity is to establish the first precision medicine, disease-modifying treatment for Parkinson's disease by successfully targeting the LRRK2 pathway.
Success could enable expansion into broader PD populations and serve as a proof-of-concept to apply the same platform approach to other neurodegenerative and neuroimmunological diseases with high unmet need.

Risk Factors

Key risks include clinical failure of NEU-411 in Phase 2, potential safety issues associated with LRRK2 inhibition, challenges in recruiting the specific genetic patient population, and competition from other companies developing LRRK2 inhibitors.
The company also faces platform risk if its AI/ML discovery engine fails to yield additional candidates.

Competitive Landscape

Neuron23 operates in the competitive LRRK2 inhibitor space for Parkinson's, facing rivals like Biogen (partnered with Denali Therapeutics on BIIB122/DNL151) and other biotech firms. Its key differentiator is its integrated AI/ML and genetics platform for target discovery and patient stratification, aiming for a precision medicine approach from the outset.

More companies in AI / Machine Learning →More companies in United States →